How is Blincyto taken / administered?
Blincyto (blinatumomab) is a cancer treatment given as a continuous IV infusion over 28 days. You then have a break with no treatment. This is called a treatment cycle which includes the treatment days and treatment-free days.
How many treatment cycles you have will depend on which type of acute lymphoblastic leukemia (ALL) you are treating.
MRD-positive B-cell Precursor ALL:
- One induction cycle (28 days treatment, 14 days no treatment)
- Up to three additional cycles for consolidation (28 days treatment, 14 days no treatment)
Relapsed or Refractory B-cell Precursor ALL:
- Two induction cycles (28 days treatment, 14 days no treatment)
- Three additional cycles for consolidation (28 days treatment, 14 days no treatment)
- Up to four additional cycles of continued therapy (28 days treatment, 56 days no treatment)
Cycles may be interrupted due to adverse reactions.
For more information on dosage and administration of Blincyto click here: Dosage and administration of Blincyto
- Blincyto Professional Information: Accessed July 10, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125557s023s026lbl.pdf
- Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date: Accessed 24 February 2021 : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173178/
Related medical questions
- What are monoclonal antibodies?
- How much does Blincyto (blinatumomab) cost?
- Is Blincyto (blinatumomab) chemotherapy?
- How does Besponsa work to treat Acute Lymphoblastic Leukemia (ALL)?
- What is the lifetime or cumulative dose for Adriamycin?
- What to avoid when taking Gleevec?
- How much does Tecartus cost?
- Gleevec vs Sprycel vs Tasigna - how do they compare?
- How long does it take Sprycel (dasatinib) to start working?
- Is Sprycel a chemotherapy drug?
- Is Tecartus a one-time treatment?